These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 28554757)

  • 1. Clinicopathological significance and prognostic role of EZH2 expression in non-small cell lung cancer.
    Kim NY; Pyo JS
    Pathol Res Pract; 2017 Jul; 213(7):778-782. PubMed ID: 28554757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer.
    Inoue Y; Yoshimura K; Kurabe N; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
    Oncotarget; 2017 Jan; 8(5):8738-8751. PubMed ID: 28060732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of MAT3 gene expression in NSCLC.
    Zheng S; Du Y; Chu H; Chen X; Li P; Wang Y; Ma Y; Wang H; Zang W; Zhang G; Zhao G
    Diagn Pathol; 2013 Oct; 8():166. PubMed ID: 24107548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer.
    Xu XY; Lin N; Li YM; Zhi C; Shen H
    Pathol Res Pract; 2013 Jun; 209(6):345-52. PubMed ID: 23602236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of EZH2 in Non-Small-Cell Lung Cancers: A Meta-Analysis and Bioinformatics Analysis.
    Fan K; Zhang CL; Qi YF; Dai X; Birling Y; Tan ZF; Cao F
    Biomed Res Int; 2020; 2020():2380124. PubMed ID: 33299862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 protein expression associates with the early pathogenesis, tumor progression, and prognosis of non-small cell lung carcinoma.
    Behrens C; Solis LM; Lin H; Yuan P; Tang X; Kadara H; Riquelme E; Galindo H; Moran CA; Kalhor N; Swisher SG; Simon GR; Stewart DJ; Lee JJ; Wistuba II
    Clin Cancer Res; 2013 Dec; 19(23):6556-65. PubMed ID: 24097870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome.
    Wang X; Du Z; Li L; Shi M; Yu Y
    Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
    Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
    Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of caveolin-1 is correlated with disease stage and survival in lung adenocarcinomas.
    Zhan P; Shen XK; Qian Q; Wang Q; Zhu JP; Zhang Y; Xie HY; Xu CH; Hao KK; Hu W; Xia N; Lu GJ; Yu LK
    Oncol Rep; 2012 Apr; 27(4):1072-8. PubMed ID: 22200856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
    He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
    Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
    Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
    Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.
    Anagnostou VK; Lowery FJ; Zolota V; Tzelepi V; Gopinath A; Liceaga C; Panagopoulos N; Frangia K; Tanoue L; Boffa D; Gettinger S; Detterbeck F; Homer RJ; Dougenis D; Rimm DL; Syrigos KN
    BMC Cancer; 2010 May; 10():186. PubMed ID: 20459695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of SIRT1 and cortactin is associated with progression of non-small cell lung cancer.
    Noh SJ; Baek HA; Park HS; Jang KY; Moon WS; Kang MJ; Lee DG; Kim MH; Lee JH; Chung MJ
    Pathol Res Pract; 2013 Jun; 209(6):365-70. PubMed ID: 23702379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancer of zeste homolog 2 is a novel prognostic biomarker in nonsmall cell lung cancer.
    Huqun ; Ishikawa R; Zhang J; Miyazawa H; Goto Y; Shimizu Y; Hagiwara K; Koyama N
    Cancer; 2012 Mar; 118(6):1599-606. PubMed ID: 21837672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin-like growth factor receptor 1 (IGF1R) expression and survival in non-small cell lung cancer patients: a meta-analysis.
    Zhao S; Qiu Z; He J; Li L; Li W
    Int J Clin Exp Pathol; 2014; 7(10):6694-704. PubMed ID: 25400749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of immunohistochemical expression of cancer/testis tumor-associated antigens (MAGE-A1, MAGE-A3/4, NY-ESO-1) in patients with non-small cell lung cancer.
    Grah JJ; Katalinic D; Juretic A; Santek F; Samarzija M
    Tumori; 2014; 100(1):60-8. PubMed ID: 24675493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma.
    Matsubara T; Toyokawa G; Takada K; Kinoshita F; Kozuma Y; Akamine T; Shimokawa M; Haro A; Osoegawa A; Tagawa T; Mori M
    PLoS One; 2019; 14(5):e0215103. PubMed ID: 31042721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.